Search results
Results from the WOW.Com Content Network
In 1979 a new edition was published with a new title, The Pharmaceutical Codex. The Medicines Commission had recommended in 1972 that the British Pharmacopoeia should henceforth be the only compendium of official standards for medicines in the UK, and the BPC lost its status as an official book. The PSGB remained as the publishers.
Martindale Pharma – Martindale Pharmaceuticals - Ltd (Now Ethypharm UK) Mölnlycke – Mölnlycke Health Care Ltd; Mayne – Mayne Pharma plc; McNeil – McNeil Laboratories Ltd; Meda – Meda Pharmaceuticals Ltd; Medac – Medac (UK), Scion House, University of Stirling; MediSense – MediSense, Abbott Laboratories Ltd; Menarini – A ...
The British Pharmacopoeia (BP) is the national pharmacopoeia of the United Kingdom.It is an annually published collection of quality standards for medicinal substances in the UK, which is used by individuals and organisations involved in pharmaceutical research, development, manufacture and testing.
Martindale: The Complete Drug Reference is a reference book published by Pharmaceutical Press listing some 6,000 drugs and medicines used throughout the world, including details of over 125,000 proprietary preparations. It also includes almost 700 disease treatment reviews.
A British Approved Name (BAN) is the official, non-proprietary, or generic name given to a pharmaceutical substance, as defined in the British Pharmacopoeia (BP). [1] The BAN is also the official name used in some countries around the world, because starting in 1953, proposed new names were evaluated by a panel of experts from WHO in conjunction with the BP commission to ensure naming ...
Jones was a postdoctoral researcher between 1967 and 1968. From 1972 until 1975, Jones was head of development at The Boots Co Ltd.During his time there he was responsible for the technical development of several new products, notably Prothiaden (antidepressant) and Froben (anti-inflammatory), a range of generic products and the technology transfer of Brufen/Nurofen (anti-inflammatory) to many ...
The Royal Pharmaceutical Society was founded on 15 April 1841 as the Pharmaceutical Society of Great Britain, and headquartered at 17 Bloomsbury Square, London. Among its founding members were Jacob Bell and William Allen. The Northern British (Scottish) branch began the same year with nine founders including William Flockhart and John Duncan. [3]
The MHRA and the US Food and Drug Administration were criticised in the 2012 book Bad Pharma, [43] and in 2004 by David Healy in evidence to the House of Commons Health Committee, [44] for having undergone regulatory capture, i.e. advancing the interests of the drug companies rather than the interests of the public.